Synthesis and biological evaluation of novel aniline-derived asiatic acid derivatives as potential anticancer agents. 2014

Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
State Key Laboratory Cultivation Base for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry & Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, PR China.

Asiatic acid (AA) derivatives 4 and 5 modified at the C-11 and C-28 positions were designed and synthesized, their structures were confirmed using HRMS, (1)H NMR and (13)C NMR. In vitro antitumor activities of all compounds against MGC-803, NCI-H460, HepG2, Hela and 7404 cancer cell lines were evaluated and compared with commercial anticancer drug 5-fluorouracil (5-FU), employing standard MTT assay. The new compounds 5a-5t showed stronger anti-proliferative activity than AA, especially compound 5b was found to be the best inhibition activity on HepG2 cell line. In addition, the mechanism of compound 5b was preliminarily investigated by acridine orange/ethidium bromide staining, Hoechst 33258 staining, JC-1 mitochondrial membrane potential staining, flow cytometric, qRT-PCR (quantitative real-time PCR) and Western blot. Compound 5b induced the productions of ROS, and altered anti- and pro-apoptotic proteins, leading to mitochondrial dysfunction and activations of caspase-9 and caspase-3 for causing cell apoptosis. Moreover, the cell cycle analysis showed that compound 5b mainly arrested HepG2 cells in G1 stage.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000814 Aniline Compounds Compounds that include the aminobenzene structure. Phenylamine,Phenylamines,Anilines,Compounds, Aniline
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
June 2023, Fitoterapia,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
March 2021, Bioorganic chemistry,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
June 2021, Bioorganic chemistry,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
October 2004, Bollettino chimico farmaceutico,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
January 2024, Frontiers in chemistry,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
March 2012, Molecules (Basel, Switzerland),
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
August 2021, Bioorganic & medicinal chemistry letters,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
December 2015, Chemical biology & drug design,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
March 2010, Oncology letters,
Jian-Fei Li, and Ri-Zhen Huang, and Gui-Yang Yao, and Man-Yi Ye, and Heng-Shan Wang, and Ying-Ming Pan, and Jing-Teng Xiao
August 2013, Drug discoveries & therapeutics,
Copied contents to your clipboard!